GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Other Long-Term Liabilities

Myriad Genetics (HAM:MYD) Other Long-Term Liabilities : €1.9 Mil (As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Other Long-Term Liabilities?

Myriad Genetics's other long-term liabilities for the quarter that ended in Mar. 2025 was €1.9 Mil.

Myriad Genetics's quarterly other long-term liabilities declined from Sep. 2024 (€30.9 Mil) to Dec. 2024 (€2.1 Mil) and declined from Dec. 2024 (€2.1 Mil) to Mar. 2025 (€1.9 Mil).

Myriad Genetics's annual other long-term liabilities increased from Dec. 2022 (€17.0 Mil) to Dec. 2023 (€37.9 Mil) but then declined from Dec. 2023 (€37.9 Mil) to Dec. 2024 (€2.1 Mil).

Myriad Genetics Other Long-Term Liabilities Historical Data

The historical data trend for Myriad Genetics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Other Long-Term Liabilities Chart

Myriad Genetics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.10 4.96 16.99 37.87 2.10

Myriad Genetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.35 32.14 30.91 2.10 1.85

Myriad Genetics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Myriad Genetics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Other Long-Term Liabilities
Comparable Companies
CSTL FLGT CDNA PSNL STIM ATLN OPK NEOG LDDD ACRS TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT
Traded in Other Exchanges
MYGN:USA 0K3W:UK MYD:Germany
Address
322 North 2200 West, Salt Lake City, UT, USA, 84116
Website
https://www.myriad.com
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.